Omnicell, Inc. $OMCL Holdings Raised by Liontrust Investment Partners LLP

Key Points

• Liontrust Investment Partners LLP increased its stake in Omnicell, Inc. by 7.3%, owning a total of 175,655 shares valued at approximately $6.14 million.
• Omnicell's stock has a market capitalization of $1.45 billion and reported earnings of $0.45 per share, surpassing analysts' estimates.
• Analysts rate Omnicell as a "Moderate Buy" with a consensus target price of $46.71, despite recent adjustments to price targets from other investment firms.

Liontrust Investment Partners LLP grew its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 7.3% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 175,655 shares of the company's stock after buying an additional 11,981 shares during the quarter. Liontrust Investment Partners LLP owned 0.37% of Omnicell worth $6,141,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in OMCL. Principal Financial Group Inc. raised its holdings in Omnicell by 2.6% during the first quarter. Principal Financial Group Inc. now owns 244,644 shares of the company's stock worth $8,553,000 after purchasing an additional 6,288 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Omnicell in the 1st quarter valued at approximately $2,073,000. Jane Street Group LLC increased its position in Omnicell by 7.4% during the 4th quarter. Jane Street Group LLC now owns 54,282 shares of the company's stock worth $2,417,000 after purchasing an additional 3,725 shares during the period. Invesco Ltd. raised its stake in shares of Omnicell by 2.4% during the 4th quarter. Invesco Ltd. now owns 219,453 shares of the company's stock worth $9,770,000 after buying an additional 5,063 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new position in shares of Omnicell during the 1st quarter worth approximately $901,000. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Stock Down 0.5%

Omnicell stock traded down $0.16 during midday trading on Wednesday, hitting $31.75. 516,267 shares of the company were exchanged, compared to its average volume of 604,951. The company has a market cap of $1.46 billion, a PE ratio of 63.50, a price-to-earnings-growth ratio of 9.31 and a beta of 0.78. The company's fifty day moving average price is $29.49 and its 200-day moving average price is $32.07. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.30 by $0.15. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The business had revenue of $290.56 million for the quarter, compared to analysts' expectations of $275.57 million. During the same quarter in the previous year, the firm posted $0.51 earnings per share. The company's revenue was up 5.0% compared to the same quarter last year. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. On average, research analysts predict that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on OMCL. Piper Sandler decreased their price target on Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, August 11th. Benchmark decreased their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Bank of America increased their price target on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a report on Friday, May 23rd. Wells Fargo & Company boosted their price objective on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a report on Monday, July 21st. Finally, Wall Street Zen lowered shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Omnicell currently has a consensus rating of "Moderate Buy" and an average price target of $46.71.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.